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ABSTRACT 
Anabolic steroids (AS) derived from testosterone 
have both anabolic (muscle and strength enhan- 
cing) and androgenic  (pr imary and secondary 
sexual) effects. Efforts to limit the androgenic while 
enhancing the anabolic effects have not been suc- 
cessful. Alterations to the structure of testostero- 
ne, so as to improve the pharmacokinetics of AS, 
have resulted in drugs, which are orally active, 
have a longer plasma half life and may be adminis- 
tered as depot injections. Therapeutic doses of AS 
produce statistically significant effects on strength 
and athletic performance in well-controlled scienti- 
fic and clinical trials. At low, therapeutic doses, diet 
and an intensive training regime are equally impor- 
tant in producing a statistically significant increase 
in strength. Higher doses 6-7000mg per week are 
regularly administered in sport and produce the 
greatest increases in muscle strength erythropoie- 
sis and lean body mass. Patterns of steroid abuse 
can be complex, reflecting a desire to minimise 
side effects, and avoid detection. AS side effects 
are of many types. AS increase salt and water 
retention leading to an expansion of the blood 
volume, but effects of steroids on blood pressure 
are equivocal and most cardiovascular side effects 
appear to be reversible. 
Abuse of AS causes an increase in blood triglyceri- 
de and cholesterol levels and this is associated 
with a decline in High Density Lipoproteins (HDLs) 
and an increase in the Low Density (LDL) type. 
Though these effects are reversible they are asso- 
ciated with an increased risk of both acute and 
chron ic  card iovascu lar  patho logy .  The most  
serious irreversible anabolic steroid side effects 
are associated with carcinomas - mainly of the 
liver, prostate and kidney. Hepatic carcinomas are 
strongly associated with abuse of the orally active 
17alpha methyl substituted steroids, which also 
produce a reversible jaundice. In males, anabolic 
steroid abuse causes suppression of LH and FSH 
release leading to inhibition of testosterone pro- 
duction often accompanied by testicular atrophy, 
and azoospermia. High, chronic doses of the drugs 
may also cause moderate to severe feminising 
effects in the form of gynaecomastia. Male secon- 
dary sexual characteristics are a side effect of AS 
abuse in women. Increased insulin resistance and 
elevated fasting blood glucose levels are the com- 
monest non-gonadal endocrine side effects of AS. 
AS abuse leads to contradictory, complex, beha- 
vioural, and psychiatric changes. Increased fre- 
quency of mental illness, in anabolic steroid abu- 
sers including paranoid schizophrenia, mania and 
depress ion  has been reported.  Phys ica l  and 
psychological dependency occur amongst some 
anabolic steroid abusers and severe psychiatric 
disorders can appear upon withdrawal, leading in a 
few cases to criminality and even suicide. We need 
more studies on the long-term effects of AS. The 
implications of the past 50 years of AS abuse will 
be discussed in the review. 
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I. INTRODUCTION 
Goethe's legendary Zauberlehrling (Sorcerer's Apprentice) 
casts a spell to save time and effort in his Master's absen- 
ce, only to find that the magic cannot be reversed. The pro- 
moters of anabolic steroid abuse are in a similar position. 
Testosterone, from which anabolic steroids are derived, 
was first isolated in 1935 and synthetic derivatives became 
commercially available from 1945. The last steroid-free 
Olympic Games is presumed to have been the controver- 
sial Berlin Olympics of 1936 [25]. 
Despite many rumours, there is no evidence that either tes- 
tosterone or anabolic steroids were administered to the 
Nazi-Waffen S-S regiments during World War 2 [86]. 
The first documented appearance of anabolic steroid in a 
major sporting event was during the World Weight lifting 
Championships in Vienna in 1954 [86]. 
Since the 1950's there have been advances in the medicinal 
chemistry and pharmacology of the anabolic steroids [42, 
78]. 
Anabolic steroids derived from testosterone have both ana- 
bolic (muscle and strength enhancing) and androgenic (pri- 
mary and secondary sexual) effects and major efforts to 
limit the androgenic while enhancing the anabolic effects 
have not been successful. Alterations to the structure of 
testosterone, so as to improve the pharmacokinetics of ana- 
bolic steroids, have resulted in drugs, which are orally acti- 
ve, have a longer plasma half-life and may be administered 
as depot injections. Orally active anabolic steroids have a 
17alpha-methyl substitution, which also increases their 
hepatic toxicity, while esterification with a long chain car- 
boxylic acid allows the anabolic steroid to be used as a 
depot drug [25, 42, 49]. 
Therapeutic doses of anabolic steroids are 2.5-10mg per 
day in the UK, and positive statistically significant effects 
on strength and athletic performance have been obtained 
using these doses in well-controlled scientific and clinical 
trials. At these low, "ethical" and therapeutic doses, diet 
and an intensive training regime are equally important in 
producing a statistically significant increase in strength 
[25]. Much higher doses 6-7000mg per week are regularly 
administered in sport and recent research as shown that 
these supra-physiological treatments produce the greatest 
increases in muscle strength and size while also increasing 
erythropoiesis. This range of doses has also been shown to 
increase the lean body mass but evidence for an effect on 
aerobic power and endurance is equivocal and awaits fur- 
ther investigation [25]. 
Patterns of steroid abuse can be complex, reflecting a desi- 
re to minimise side effects, avoid detection or fulfil some 
ritualistic desire. The commonest regimes are: cycling in 
which the dosing occurs for 6-8 weeks followed by 6-8 
weeks abstinence, pyramiding in which the drug is slowly 
built up and then reduced, and stacking in which several 
steroids, with different pharmacokinetic properties, are 
used together. There are female versions of these dosage 
programmes particularly for the cyclic type. 
Anabolic steroid side effects are of many types. They may 
be short or long term, acute or chronic, reversible or irre- 
versible, masculinising or feminising, systemic and/or  
behavioural [25]. Much more is known about the short- 
term effects of anabolic steroids despite 50 years of their 
abuse. Anabolic steroids increase salt and water retention 
leading to an expansion of the blood volume, but studies 
on the effect of steroids on blood pressure are equivocal 
and most of these cardiovascular side effects appear to be 
reversible [62]. However, ventricular abnormalities inclu- 
ding hypertrophy have been recognised in several recent 
studies of chronic steroid abusers though these have invol- 
ved only small numbers of subjects. Abuse of anabolic ste- 
roids causes an increase in blood triglyceride and choleste- 
rol levels and this is associated with a decline in High Den- 
sity Lipoproteins (HDLs) and an increase in the Low Den- 
sity (LDL) type [25, 49]. Though these effects are reversi- 
ble they are associated with an increased risk of both acute 
and chronic cardiovascular pathology. Some of the patho- 
logical changes, which occur, may be easily detected in 
terms of an adverse blood lipid profile, but there are also 
subtle pathologies of the vascular endothelium which 
contribute to atherosclerosis [18]. 
Some of the most serious irreversible anabolic steroid side 
effects are associated with carcinomas - mainly of the 
liver, prostate and kidney. Hepatic carcinomas are strongly 
associated with abuse of the orally active 17alpha-amethyl 
substituted steroids, which are also prone to produce a 
reversible jaundice [25]. 
In males, anabolic steroid abuse is known to cause sup- 
pression of LH and FSH release leading to inhibition of 
endogenous testosterone production. This may be accom- 
panied by testicular atrophy, and a reversible and someti- 
mes irreversible azoospermia. High, chronic doses of the 
drugs may also cause moderate to severe feminising effects 
in the form of gynaecomastia. The mammary development 
is caused by the "aromatisation" of testosterone or other 
steroids (but not nandrolone) to oestradiol [49]. 
Male secondary sexual characteristics are a side effect of 
anabolic steroid abuse in women. They include growth of 
facial hair, deepening of the voice, pharyngeal enlarge- 
ment, clitoral growth and skeletal changes. Though ame- 
norrhoea is often found in female endurance athletes, ste- 
roid induced amenorrhoea may be permanent and when 
reversed may still be associated with infertility. 
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Acne is the most common dermatological side effect of 
anabolic steroids and is particularly resistant to standard 
therapies. It is not always reversible. 
Increased insulin resistance and elevated fasting blood glu- 
cose levels are the commonest non-gonadal endocrine sid  
effects of anabolic steroids. They are usually reversible 
and the insulin resistance does not normally lead to Type II 
diabetes [25]. 
Abuse of anabolic steroids leads to complex behavioural, 
psychological nd psychiatric changes upon which there is 
little agreement [25, 42]. Many of the studies are contra- 
dictory and have been carried out in different and non- 
comparable groups of either athletes or non-athletes and 
often, different outcomes or psychological variables are 
being measured. Some studies indicate that aggression is
increased in anabolic steroid abusers while others limit this 
to increases in sexual aggression arguing that an increased 
level of "controlled" aggression is necessary in the suc- 
cessful athlete [25]. Several investigators have found evi- 
dence of increased frequency of mental illness, as categori- 
sed by DSM IV and WHO criteria, in AS abusers, inclu- 
ding paranoid schizophrenia, mania and depression [40, 
55]. Equally disturbing are reports of physical and psycho- 
logical dependency amongst some anabolic steroid abuser 
[11] and severe psychiatric disorders occurring upon with- 
drawal, leading in a few cases to criminality and even sui- 
cide [55]. 
We urgently need more studies on the long-term effects of 
anabolic steroids. One study carried out on steroid-abusing 
power lifters in Finland, suggests that anabolic steroid 
abuse reduces longevity: they were 4.6 times more likely 
to suffer a premature death than non-abusers [ 11 ]. 
In the following sections, evidence for the action and side 
effects of anabolic steroids will be assessed and discussed. 
II. TESTOSTERONE AND RELATED 
COMPOUNDS 
Testosterone and its synthetic and semi-synthetic derivati- 
ves and its immediate precursors are termed C-19 steroid 
hormones, a classification based on the structure of the ste- 
roid androstane (Figure 1) [25]. When testosterone is syn- 
thesised in humans, its isomer epi-testosterone is also pro- 
duced (Figure 1). After the discovery and isolation of tes- 
tosterone in 1935, it was demonstrated that testosterone 
possessed both anabolic and androgenic properties [25, 
42]. It has proved almost impossible to separate these 
pharmacological ctivities [25, 42, 86]. Steroids, which 
mimic the action of testosterone, are known as anabolic 
androgenic steroids (AAS) or simply as anabolic steroids 
(AS). 
1. Testosterone Biosynthesis 
Testosterone (T) originates like all steroid hormones, from 
cholesterol, but the immediate precursor is androstenedio- 
ne, which is converted to testosterone bythe enzyme 17-g- 
hydoxysteroid dehydrogenase (Figure 2) [25, 42, 75]. 
Recently, it has been discovered that the anabolic steroid 
nandrolone, which is 19-nortestosterone (Figure 1), can be 
formed in both males and females from 19-nor androstene- 
dione [81]. The implications of this are discussed later and 
in also in detail by George [25] in a previous review. 
2. Testosterone metabolism 
Testosterone and its 19-nor derivative, nandrolone ar  
converted to etiocholanolone and androsterone and their 
respective 19-nor derivatives by the hepatic 3alpha/3 beta 
keto reductase nzyme system [75, 81]. Testosterone and 
nandrolone may be converted by 5 alpha-reductase to their 
respective dihydro derivatives, but of these two only tes- 
tosterone can be converted to oestradiol by aromatase [75, 
81, 83]. 
3. Actions of testosterone and anabolic steroids 
Testosterone produces its effects at the cellular level by : 
1. diffusing across the cell membrane and binding to the 
cytosolic androgen receptor ; 
2. conversion within the target cell to DHT (via the enzy- 
me 5 alpha-reductase) ; 
3. conversion in certain target cells to oestradiol via the 
aromatase enzyme system and binding then to the cyto- 
solic oestradiol receptor. 
All the above mechanisms involve the transfer of the 
receptor/hormone complex formed subsequently, to a hor- 
mone responsive element (HRE) in the genome. 
Testosterone and possibly also AS may influence cellular 
activity by : 
4. binding to and activating cell surface membrane recep- 
tors and consequently the activation of second messen- 
ger systems; 
5. binding to modulatory (facilitatory or attenuator) sites 
associated with certain functional cell surface receptors 
such as the GABA A receptor [29], particularly at its low 
affinity benzodiazepine binding site [84]. 
Testosterone and AS possess androgenic and anabolic 
effects. Modifications of the testosterone structure are of 3 
major types: A, B and C. Esterification of thel7 beta-OH 
group with a long chain fatty acid produces Type A. The 
type B modification involves alkyl substitution at the 17 
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Figure 1 : The structure of  testosterone and some of its synthetic derivatives - adapted from George [25]. 
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Figure 2 : The biosynthesis of testosterone and its derivatives - adapted from George [25]. 
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groups usually to positions 1-5. Type A substitutions pro- 
duce injectable/depot preparations, Type B modifications 
confer oral activity, while type C changes reduce metabo- 
lism of the steroid. A full discussion of the impact of these 
modifications has been provided in a number of reviews 
[24, 25, 42, 49, 78]. Though the above changes also induce 
alterations in the ratio of anabolic / androgenic activity, 
some androgenic activity is still present in all AS [25, 42]. 
4. Patterns of administration 
The pattern and route of administration of anabolic ste- 
roids varies from one group of abusers to another. It is 
determined as much by anecdotal evidence of efficacy as 
by deliberate attempts to avoid the detection of abuse by 
sporting and athletic authorities. Detailed reviews and ana- 
lysis of AS administration regimes [25, 42] have yielded 3 
major patterns which have been summarised as follows 
[25]: 
a) Cycling : a period of drug administration followed by an 
equivalent period of abstinence ; then the drug is recom- 
menced in a continuing pattern e.g. 6-8 weeks on/6-8 
weeks off/6-8 weeks on etc. There may be intricate pat- 
terns of drug administration a d short breaks or vice versa. 
Patterns of abstinence can be timed to coincide with com- 
petitions in order to avoid detection but the overall strategy 
is to reduce the incidence of side-effects [25, 43]. 
b) Pyramiding is a variation of cycling in which the dose 
is gradually built up in the cycle to a peak and then gra- 
dually reduced again towards the end of the cycle [25]. 
The regime is said to cause fewer behavioural side effects, 
such as Iowered mood, caused by the withdrawal of the 
drug, though there is no published evidence of this. 
c) Stacking involves the use of more than one anabolic ste- 
roid at a time. A stacking regime involves the simultaneous 
use of both an orally administered steroid and an injectable 
one. More <<sophisticated>> patterns involve intricate pat- 
terns of administration using many different steroids each 
with supposedly different pharmacological profiles. The 
aim of this technique is to avoid so-called plateauing ; that 
is the development of tolerance to a particular drug. These 
<<super stacking" programmes are "designed" to maximise 
the occupation of cytosolic receptor sites. This is very 
dubious pharmacology since the number of intracellular 
testosterone/DHT steroid receptors is stable and all are 
probably saturated under normal physiological conditions, 
or at least when therapeutic doses of AS are used. The effi- 
cacy of this administration scheme has recently been chal- 
lenged by others [43]. However, it is quite possible that the 
supra-physiological doses administered during stacking 
and the consequent supra-physiological AS plasma levels 
that result from this may lead to a displacement of gluco- 
corticoids (GC) from the GC receptor leading to a reduc- 
tion in GC-induced protein catabolism [25, 62]. Such 
supra-physiological doses are at least 100 times those indi- 
cated for therapeutic use in the EU and US [63]. 
An alternative xplanation is that the androgen receptor 
may be upregulated by supra-physiological AS doses [42], 
but this does not explain why supraphysiological doses of 
testosterone are able to reverse the muscle wasting present 
in individuals with androgen insensitivity syndromes [83]. 
In addition to the abuse of AS in complex patterns and 
cycles, other non-steroidal "anabolic" agents may be co- 
administered. Human chorionic gonadotrophin (hCG) is 
often abused by athletes to stimulate natural testosterone 
secretion from the testis [20] as this hormone has an LH 
like effect on the testicular Leydig cells [26]. Such abuse 
of hCG is frequently employed to counteract the suppres- 
sion of LH induced by chronic AS administration [26]. 
Abuse of growth hormone (GH) is suggested to reduce 
some of the lipid-elevating side effects of anabolic steroids 
- but there is no published evidence that this is true [25]. 
5. Dosage 
In the UK, the standard maintenance dosage of testostero- 
ne in males, ranges from 40-120mg.d-1. This is signifi- 
cantly less than the doses recorded in many clinical/scien- 
tific studies of anabolic steroids [25, 42, 63, 78]. A dose- 
response curve of the effect of anabolic steroid administra- 
tion on lean body mass [21, 42] shows that such doses are 
at the base of the D-R curve while the maximum effect 
was achieved with doses in excess of 5000rag per week! 
Several recent studies have shown conclusively that these 
massive doses when used under controlled conditions pro- 
duce statistically significant increases in muscle strength 
and lean body mass compared to both placebo and to "nor- 
mal" clinical doses [7, 8]. 
I lL DO ANABOLIC STEROIDS WORK IN 
SPORT ? 
Until recently, the results of the effects of physiological 
doses of testosterone or anabolic steroids on muscle 
strength and athletic performance were often conflicting 
[25, 46]. Major reviews of the published ata since 1975 
have highlighted crucial errors in the experimental tech- 
niques, conditions, evaluation criteria, statistical design, 
doses, and subjects used in the papers published in this 
period [19, 25, 42, 78]. Some early studies made no use of 
placebo r did not standardise their doses or use non-repro- 
ducible means of strength assessment [19, 65, 78]. Revie- 
wers have often confused and compared studies using 
congenitally or pathologically hypogonadal men with 
those in which normal or exercising subjects were used 
[42]. 
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In 1975 one of the first scientifically controlled, cross-over 
studies demonstrated a small but significant increase in 
strength in subjects taking clinical doses of AS compared 
to controls [22]. It was established in 1980, that low doses 
of anabolic steroids produce a significant effect on muscle 
strength only in trained athletes who exercise regularly and 
intensively and who maintain a high protein intake [34, 
80]. Thus these aspects must all be controlled in an investi- 
gation of AS action. Exercise and training regimes cause 
increases in muscle mass and strength which are often dif- 
ficult to differentiate from the effects of low doses of ana- 
bolic steroids [25]. Once early experimenters had establis- 
hed that therapeutic doses of anabolic steroids do increase 
muscle strength, it was then questioned as to whether the 
high doses used by many abusers were necessary. 
There is an obvious ethical problem in submitting normal 
subjects to doses of AS in excess of 5000mg per week. 
However, a number of research groups have now establis- 
hed unequivocally that anabolic steroids in supra-physiolo- 
gical doses in maximally trained athletes do produce statis- 
tically significant increases in muscle strength and mass [7, 
8]. Results from biopsy studies in weightlifters show that 
the number of muscle fibres and the average fibre size in 
muscles uch as the trapezius were increased in anabolic 
steroid abusers compared to non-abusers [38]. The effect 
of AS on the human deltoid muscle, has been localised to 
an increase in size in the Type II muscle fibres [31] and 
this complements earlier studies showing that, at least in 
mammals, testosterone differentially increases the size of 
slow twitch rather than fast twitch muscles [42, 66]. As a 
generalisation, testosterone and therefore, probably all ana- 
bolic steroids, increase upper body muscle power more 
than lower body power, and increase maximal voluntary 
strength and leg power but have little effect on muscle fati- 
gability or muscle tension [70]. 
What determines the adult human response to T and AS ? 
In adult males there is considerable thnic variation in 
serum concentrations of both T and Sex Hormone Binding 
Globulin (SHBG) [33]. SHBG is a major determinant of
the bioavailibity of T in males and females [33]. Total 
Bound and calculated free T have been found to be lower 
in Pakistani men than in either Caucasians or Afro-Carib- 
beans [33]. These results need further evaluation in order 
to elucidate the possible influence of SHBG on anabolic / 
androgen responsiveness. 
Since AS and T are known to produce most of their effects 
via interaction with a genomic Hormone Response Ele- 
ment (HRE), it might be expected that polymorphisms of
this Androgen Receptor (AR) gene might correlate with 
differences in the general responsiveness to AS, since at 
least one research group has demonstrated a relationship 
between the increased length of the AR gene (in terms of 
increased numbers of repeats of the trinucleotide CAG) 
and reduced susceptibility to prostate cancer [33]. Howe- 
ver, a recent study has shown only weak association bet- 
ween CAG-repeat polymorphisms of the AR gene and the 
response to T in terms of thigh muscle volume and lean 
body mass [79]. The major determinants of T responsive- 
ness in this study were age, dose of T and the serum 
concentration of prostate specific antigen [79]. However, 
AR numbers must have some influence over the response 
to AS in humans ince AR receptor upregulation has been 
reported in muscle exposed to supraphysiological doses of 
AS [68]. This controversy may be resolved by the recent 
observation that different muscles uch as the trapezius and 
vastas lateralis contain different concentrations of AR and 
respond ifferently in terms of AR receptor upregulation i
response to training and AS [39]. 
IV .  ANABOLIC  STEROID S IDE EFFECTS 
The side effects of anabolic steroids occurring as a result 
of clinical doses of the drugs are well documented and 
have been discussed in detail recently [10, 25, 42, 43, 49]. 
One of the commonest side effects is sodium retention 
which gives rise to water retention and then oedema [32, 
62]. Water etention and increased erythropoesis contribute 
to an increase in blood volume [42, 62] and also to the 
increased weight gain that occurs following anabolic ste- 
roid administration [32, 43]. Much of the initial increase in 
muscle size and bulk that occurs following AS administra- 
tion is due to the retention of water in the muscle tissue 
and not to an increase in protein content or muscle fibres 
[32, 63]. More serious side-effects, associated with the 
prolonged use of AS, include jaundice and hepatic arcino- 
ma [28, 43]. In males, additional side effects include sup- 
pression of LH and FSH secretion leading to atrophy of the 
testis [76], severe reductions in or cessation of testosterone 
secretion [17, 76] and azoospermia [36]. There is an 
increased risk of prostate hyperplasia and possibly prosta- 
tic carcinoma [43]. Side effects in females include the 
appearance of male secondary sexual characteristics and 
the suppression of menstruation [25, 42, 43]. Paediatric use 
of AS can cause growth stunting via epiphyseal closure 
and also precocious puberty in male children [10, 25, 43]. 
Many different types of study indicate that AS induce fee- 
lings of increased energy, well being, improved mood and 
increased aggressiveness [10, 28]. Generally, studies and 
reviews of behavioural effects of AS concentrate heavily 
on the negative ffects on behaviour, which may only be 
seen at the high doses administered in sporting abuse [43]. 
It should be emphasised that some of the negative ffects 
observed after the administration f AS may be due to the 
effect of changes induced in the secretion of other hormo- 
nes and not a direct action of AS themselves [17]. This is 
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discussed in a later section along with the negative and 
addictive ffects of AS. There is no evidence in the current 
scientific or clinical literature that AS addiction occurs 
when AS are administered attherapeutic doses [10]. 
V. ANABOLIC  STEROID S IDE EFFECTS IN 
SPORTING ABUSE 
Some of the side effects that occur as a result of abuse in 
sport are simply amplifications of those previously descri- 
bed. However, the supraphysiological doses commonly 
taken by cheating athletes cause additional side effects, 
some of which are reversible upon cessation of steroid 
abuse but may also cause chronic and irreversible side 
effects [42]. The long-term effects and other side effects of 
anabolic steroid abuse is an under esearched but important 
topic [25]. 
1. Hypothalamic pituitary and endocrine side effects 
Acute and chronic administration of AS suppresses the 
plasma levels of gonadotrophins [76], testosterone [17] 
and thyroid hormones T3 and T4, but has an insignificant 
effect on pituitary-adrenal hormones [17]. In a recent 
study, changes in aggressiveness during administration of 
methyl testosterone correlated specifically with increases 
in free plasma thyroxin [17]. These paradoxical findings 
with thyroid hormones add to the debate about the direct 
and indirect role of AS and behavioural changes. A more 
serious side effect of AS on the hypothalamico-pituitary 
axis has also been reported recently in a male body-buil- 
der in whom there was severe hypogonadism, and plasma 
FSH and LH levels were undetectable but the sperm count 
was normal [76]. These abnormalities were present 3 
months after the cessation of AS abuse and the patient 
eventually became ugonadal only after treatment with 200 
microgrammes of LHRH on 3 consecutive days [76]. 
Gynaecomastia sometimes occurs in athletes abusing 
moderate to high doses of AS [23] and the frequency of 
this side effect increases with chronic abuse [23]. The 
breast enlargement is caused by the aromatisation of cer- 
tain AS such as T, but not nandrolone, to oestradiol [49]. It 
is for these reasons that AS abusers concomitantly admi- 
nister tamoxifen, an oestradiol receptor antagonist, and 
also aminoglutethimide, an aromatase inhibitor [23]. 
Anabolic steroids have been shown to increase insulin 
resistance in one study [13], while in another, nandrolone 
but not testosterone, increased glucose uptake into muscle 
[35]. It is suggested that the ability of an AS to be aromati- 
sed to oestradiol may influence its effect on glucose 
homeostasis [35.] 
2. Cardiovascular side effects 
Cardiovascular side effects are possibly the most intensive- 
ly researched consequences of anabolic steroid abuse. Ana- 
bolic steroids have been shown to increase the blood volu- 
me but in 8 of the nine cases reviewed by Rockhold [62] 
the subjects were non-athletes. In athletes treated with 
methandionone, there was a 15% increase in total blood 
volume. Most of these studies, including the one contai- 
ning athletes, failed to control for treatment; so the increa- 
se in blood volume could have been due to increased ery- 
thropoiesis and not to a direct increase in the blood volume 
[621. 
There are many documented studies and reports showing 
that hypertension is linked to anabolic steroid abuse [28, 
72, 80], but others show minimal or contradictory effects 
or no effect on blood pressure [62]. It has also been sug- 
gested that hypertension may be induced by only certain 
types of AS [62]. Ventricular function in animals is impai- 
red by administration of anabolic steroids [51 ] and the 
pathological changes that appear are similar to those found 
at autopsy in sportsmen who have been abusing AS [2]. In 
intensely training athletes, AS induce left ventricular thic- 
kening, an increase in the end-diastolic volume and relaxa- 
tion index [80]. A study by Niemmen reported the above 
findings and also cardiac hypertrophy in 4 young weigh- 
tlifters. 2 of its four weightlifters additionally had symp- 
toms of heart failure and one developed a massive throm- 
bosis in both ventricles [2]. 
The micro-vascular effects of anabolic steroid abuse have 
been investigated recently. Ebenbichler et al [ 18] examined 
arteriolar flow mediated ilatation (FMD) in 20 non-smo- 
king body-builders. They found that FMD was reduced in 
body builders compared to non-abusing controls, but GTN 
(Glyceryl TriNitrate, an anti-angina drug) induced vasodi- 
latation was reduced but not significantly. These findings 
correlated with a marked reduction in HDLC levels in 
some athletes. It could be concluded that anabolic steroid 
abuse is associated with an atherogenic blood lipid profile 
coupled with endothelial dysfunction, leading to an increa- 
sed risk of atherosclerosis. 
Anabolic steroids increase blood triglyceride and choleste- 
rol levels [2], and lower blood levels of high-density lipo- 
protein (HDL) - principally the HDL2 and HDL 3 frac- 
tions, while the concentration of low-density lipoprotein 
(LDL) is increased [2, 46]. As a result of these changes in 
the blood lipoprotein profile, the ratio of free cholesterol te 
HDL-bound cholesterol rises [48]. Testosterone appears tc 
have the least effect of all the AS on the blood lipoprotein 
profile [46]. The significance of these findings is that the 
U.S. Framingham study has shown that a mere reduction 
of 105 in the HDL concentration could increase the chan- 
ces of a coronary heart disease by as much as 25%. The 
HDL-lowering effect of AS has been determined as 25% in 
one study [15] and as high as 52% in another [62]. 
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comparison, in normal males, 25% of cholesterol is in the 
form of HDL while in AS abusers only 7.8% of cholesterol 
is HDL-bound [25]. The greatest reduction in bound cho- 
lesterol is observed with orally administered AS [46]. 
However, several studies show that the reduction in HDL- 
bound cholesterol can be reversed when the AS abuse is 
stopped [15, 45, 62]. The time for levels to return to nor- 
mal varies from 3-5 weeks [45, 62] to 6-12 weeks [15]. A 
lowering of serum HDL is a risk factor for cardiovascular 
and cerebrovascular disease [2, 45, 46], but at the same 
time total cholesterol levels may remain unchanged [27, 
43]. This may lead the AS abuser, who is monitoring his 
cholesterol levels, to a false sense of security since the 
atherosclerosis a sociated with AS abuse may not be lin- 
ked directly to cholesterol levels but to other changes in 
lipid and also triglyceride metabolism [27, 43]. In 1984, 
Goldman [28] reviewed a number of cases of fit healthy 
athletes aged <40 years who developed cardiovascular dis- 
ease (CVD) while abusing anabolic steroids. Lukas [45] 
could find only 1 case of an athlete dying of CVD while 
abusing anabolic steroids in published research up to 1992. 
One reason for these low numbers of athletes dying in an 
apparently high-risk situation is that AS abusers who are 
athletes may be fitter than the rest of the population. This 
may delay pathological changes until late in life [71 ]. One 
analysis has documented a series of cases of severe CVD 
in AS abusers. Although there was only 1 death, there were 
several severe cases that were only saved from death by 
intensive treatment and possibly their young age [71 ]. Ana- 
lysis of all these recent reviews and reports is complicated 
by the different drug regimes and doses used and by the 
life style of the participants, particularly in relation to smo- 
king [25]. This aspect needs more research. 
The above pathological changes in HDL and cardiac func- 
tion might be expected to increase blood clotting and fur- 
ther increase the risk of CVD [46]. Studies in animals sug- 
gest that AS do increase the risk of clotting disorders and 
embolism. There is an association between anabolic steroid 
abuse and increased platelet aggregation [45]. In these stu- 
dies there was one case of anabolic steroid induced stroke 
[46] and 3 cases of pulmonary embolism associated with 
anabolic steroid abuse and one case of venous thrombosis 
[71]. 
3. Hepatic and Renal Effects 
Anabolic steroids even in clinical doses, induce increases 
in liver enzyme levels [22, 32] and at higher supra physio- 
logical levels, jaundice is a frequent side-effect [43], 
though these hepatic side-effects are usually reversible 
upon cessation of AS abuse [43]. The jaundice is of the 
intra-hepatic, holestatic type 9 resulting from reduced 
flow and increased retention of bile in the bile capillaries 
of the hepatic lobules [69]. There has been one recent 
report of toxic hepatitis resulting from acute supraphysio- 
logical abuse of AS. In this case, hepato-cellular necrosis 
was confirmed by biopsy [69] and the abnormalities disap- 
peared after 12 weeks of intensive care [69]. 
The association between AS administration and hepatic 
carcinoma was first established in 1965 [28]. The 17 alpha- 
alkylated anabolic steroids are the drugs most frequently 
associated with this condition [28]. AS abuse is also asso- 
ciated with Wilms Tumour of the kidney [53]. 
4. Effects on the Prostate 
For many years there has been a suspicion that AS abuse is 
linked to prostate carcinoma. A review of 3 large case- 
controlled studies found a strong though not unequivocal 
link between increased AS levels and prostate cancer with 
T having the stongest association with this carcinoma [54]. 
An earlier more general survey of AS side-effects and 
adverse ffects found only one case of prostate cancer [71 ]. 
The risk of prostate cancer is enhanced in males by the 
presence of a polymorphism of the AR gene [50]. This 
polymorphism, involving a reduced number of repeats of 
the CAG trinucleotide is most common in African Ameri- 
cans [50]. Thus, by the use of genotyping, it may be possi- 
ble to determine, in advance, those individuals most sus- 
ceptible to this side effect. 
5. Effects on fertility 
Administration of AS inhibits the release of FSH and LH 
from the anterior pituitary in males and females [37, 47]. 
Doses of anabolic steroids as low as 15mg per day for 2 
months can cause up to 75% reduction in sperm count as 
well as azoospermia [36]. The severity of the gonadotro- 
phic suppression and the consequent anti-fertility effects 
depend on the dosage and duration of the AS abuse [47]. 
Normalisation of sperm counts after AS abuse may be 
enhanced by treatment with hCG [26, 74] or with LH-RH 
[76]. However a return of the sperm count to normal does 
not necessarily mean that the sperms produced are fertile 
[43]. Evidence that AS can cause permanent infertility are 
equivocal and one study has found no evidence of chronic 
effects in young males [71]. 
6. Effects on libido and behaviour 
Libido in males and females is influenced by testosterone 
but studies of the effects of T and AS on libido are compli- 
cated by the use of hypogonadal patients rather than eugo- 
nadal subjects. Several studies have indicated the impor- 
tance of T in maintaining key aspects of male sexuality 
such as erectile function, sexual fantasies [4, 5]. However, 
in one study doses of 500mg per week for a 14 week per- 
iod caused no increase in male libido [85]. 
There is conflicting evidence about the effects of AS on 
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behaviour. While at least one reviewer found no relations- 
hip between AS administration and increased aggression 
[3] another later survey reported unreliable and equivocal 
effects of AS on behaviour [77]. Several investigations 
have reported increased feelings of energy, aggressiveness 
and elevated mood in athletes abusing anabolic steroids [6, 
57, 64]. Using high doses in normal volunteers, 2 studies 
have shown that hostility, irritability, euphoria, drive and 
sexual arousal were increased by AS [17, 57] and another 
has shown that aggressive-responding behaviour was 
increased by AS [41 ]. However, when supra-physiological 
doses of anabolic steroids are used in normal men an 
increase in aggression is not always observed [43]. The 
underlying cause of these changes has recently been inves- 
tigated in terms of observations on plasma / serum endocri- 
ne changes [17] and changes in cerebrospinal fluid (CSF) 
composition [16]. Interestingly some behavioural changes 
have been associated with reductions in thyroid hormone 
levels [17]. 
7. Effects on mental state 
The effects of anabolic steroids on the mental state of 
patients and abusers have been shown to be as equivocal as 
the effects on behaviour. Women suffering from clinical 
post-natal depression have been shown to have low testos- 
terone levels [ 1]. AS have been shown to have anti-depres- 
sant effects in several specific groups of depressed patients 
[58, 60, 67] including HIV sufferers [60] and they have 
also been added to the treatment regime in some patients 
with treatment resistant depression [58, 67]. 
Conversely, several cases of mania have been reported in 
anabolic steroid abusers [40, 55] while depressed anabolic 
steroid abusers attempting to withdraw from anabolic ste- 
roids have become manic when treated with anti-depres- 
sant drugs [40, 77]. 
It is commonly assumed that aggressiveness and hostility 
are important components of the modem sports person's 
personality. However, this may only true of certain sports 
such as wrestling [61]. While some studies have demons- 
trated general increases in hostility and aggressiveness 
associated with AS abuse [57] others have found evidence 
of hostility, violence and physical abuse of partners by 
individuals abusing anabolic steroids [12]. However, when 
low doses of AS are used (l10-550mg per week), no 
increase in hostility could be detected [85]. At least 8 well- 
documented cases of suicide have been linked to withdra- 
wal from AS abuse [73], while analysis of CSF testostero- 
ne levels in 46 Swedish suicide attempters found lower 
Testosterone l vels than in aggressive / violent patients in 
other studies [30]. AS abuse also appears to increase the 
risk of experiencing physical violence, including murder 
[54]. 
8. Addiction and dependence 
Several studies in the 1980's have demonstrated a diction 
and dependency in male AS abusers [10, 40] but only one 
case in a female [14]. A sex steroid hormone dependency 
disorder has been described [40] and the biochemical, 
physiological and psychological factors relating to AS 
dependency have been proposed [9] and summarised [10]. 
Recently, a muscle dysmorphic syndrome has been sugges- 
ted as one possible cause of dependency [56] and this may 
have several forms of expression and may be linked to 
anorexia in males [52]. Fear of "muscle meltdown" resul- 
ting from the cessation of anabolic steroid abuse has been 
proposed as one possible psychological component of AS 
addiction [25]. As early as 1989, a link between AS abuse 
and serious crime was suggested [44]. The underlying per- 
sonality of AS abusers [6] and dependents [9] has also 
recently been analysed and an association between AS 
abuse and social image conditioning has been suggested 
[82]. Personality factors uch as narcissism and low empa- 
thy have been associated with AS abuse in at least one 
study [59]. Several reviewers have emphasised that the 
majority of athletes and body builders who abuse AS do 
not report major psychiatric symptoms [6, 45] or refrain 
from doing so [45]. It is also not necessarily true that an 
AS abuser who feels more aggressive and self-reports 
more aggression will behave violently or develop a mental 
disorder [6]. 
9. Longevity 
Only in the past 5 years have there been any serious 
attempts to examine the influence of anabolic steroids on 
mortality. In a study of 62 elite power lifters in Finland, 
premature death was 4.6 times higher in AS abusers than in 
a control population who were not abusing AS [53]. A fur- 
ther examination of the subjects of this study showed that 
power-lifting itself does not increase mortality rates and so 
the increase in mortality in the earlier study was ascribed 
to the effect of AS [53, 54]. 
VI. CONCLUSION 
AS have been abused in athletes and sport for at least 
50 years [86]. Despite many detailed studies demonstra- 
ting several acute and chronic physical and mental side 
effects of anabolic steroids, most of these side effects 
appear to be reversible [45]. We urgently need more 
studies on who is likely to be most susceptible to side 
effects and what the effects of these drugs are on mor- 
tality. Outside sport, we need to be able to cure the 
social, cosmetic abuse of the drugs. Whether the Ana- 
bolic Sorcerer wig ever return to remove the anabolic 
spell remains to be seen. 
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